| Outcomes | Illustrative comparative risks (95% CI) | Relative effect (95 % CI) | No of participants (studies) | Quality of the evidence (GRADE) | |
|---|---|---|---|---|---|
| Assumed risk | Corresponding risk | ||||
| Danazol + placebo nasal spray | GnRH agonist (nafarelin IN) + oral placebo TDS | ||||
| Relief of painful symptoms – Pelvic tenderness Follow-up: 12 months1 | 742 per 1,000 | 772 per 1,000 (601 to 987) | RR 1.04 (0.81 to 1.33) | 96 (1 study) | ⊕⊝⊝⊝ very Low2,3 |
| Relief of painful symptoms – Pelvic induration Follow-up: 12 months1 | 871 per 1,000 | 906 per 1,000 (775 to 1,000) | RR 1.04 (0.89 to 1.22) | 96 (1 study) | ⊕⊝⊝⊝ Very low2,3 |
CI: confidence interval; GnRH: gonadotrophin releasing hormone; IN: intranasal; RR: risk ratio; TDS: 3 times per day
Assessed after the end of the treatment period
Quality of evidence was downgraded by 1 point owing to unclear risk of selection bias (no details about allocation concealment method and unclear description of the allocation concealment procedure)
Quality of evidence was downgraded by 2 points owing to very serious imprecision: CI crosses 2 default thresholds
From: 11, Management strategies
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.